The Future of MRD Testing: Why It Matters for Multiple Myeloma Patients and What Comes Next
Dr. Neha Korde, from Memorial Sloan Kettering Cancer Center, will join us to discuss Minimal Residual Disease (MRD) testing, it's role in monitoring multiple myeloma, and how it influences treatment decisions. We’ll cover current MRD testing techniques, including exciting advancements in blood-based MRD testing, which offer a less invasive option for patients. We will also discuss Dr. Korde's research which is looking at "Stopping Maintenance Therapy in People with Sustained MRD-Negativity", and how this may shape the future of care.
Cynthia introduces the agenda of the event and featured speaker Dr. Neha Korde
Dr. Neha Korde talks about MRD testing for myeloma patients
Type your questions in the chat and we will answer them!
Cynthia Cahoon, RN
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Neha S. Korde, MD
I am a board-certified hematologist specializing in the treatment of multiple myeloma and other plasma cell neoplasms. I have a particular research interest in early plasma cell disorders, including monoclonal gammopathy of unknown significance (MGUS) and smoldering myeloma (SMM), and understanding disease biology that may promote transition to frank symptomatic multiple myeloma in some individuals. My colleagues at Memorial Sloan Kettering Cancer Center and I offer a variety of treatment options (on and off clinical trial) for patients with multiple myeloma and high-risk SMM, including access to the latest novel drugs and immune-therapeutic approaches. Recent therapeutic advances have led to improved outcomes for people with multiple myeloma, and I am working on developing methods of monitoring minimal residual disease. By understanding mechanisms of tumor resistance with current available drugs and monitoring techniques, we aim to drive myeloma research forward and develop new strategies of tumor control or eradication.